chr4:1801841:C>G Detail (hg38) (FGFR3)
Information
Genome
Assembly | Position |
---|---|
hg19 | chr4:1,803,568-1,803,568 View the variant detail on this assembly version. |
hg38 | chr4:1,801,841-1,801,841 |
HGVS
Type | Transcript | Protein |
---|---|---|
RefSeq | NM_001163213.1:c.746C>G | NP_001156685.1:p.Ser249Cys |
NM_022965.3:c.734C>G | NP_075254.1:p.Ser245Cys | |
NM_000142.4:c.746C>G | NP_000133.1:p.Ser249Cys |
Summary
MGeND
Clinical significance | |
Variant entry | |
GWAS entry | |
Disease area statistics | Show details |
Frequency
JP | HGVD:[No Data.] |
ToMMo:[No Data.] | |
NCBN:[No Data.] | |
NCBN(Hondo):[No Data.] | |
NCBN(Ryukyu):[No Data.] | |
East asia | ExAC:<0.001 |
Prediction
ClinVar
Clinical Significance |
![]() |
Review star | ![]() |
Show details |
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
Clinical significance | Last evaluated | Review status | Condition | Origin | Links |
---|---|---|---|---|---|
![]() |
2023-02-23 | criteria provided, multiple submitters, no conflicts | Thanatophoric dysplasia type 1 |
![]() ![]() ![]() |
Detail |
![]() |
2016-01-01 | criteria provided, single submitter | cervical cancer |
![]() ![]() |
Detail |
![]() |
2017-07-24 | criteria provided, single submitter | Malignant tumor of urinary bladder |
![]() |
Detail |
![]() |
2005-05-01 | no assertion criteria provided | seborrheic keratosis |
![]() |
Detail |
![]() |
2023-12-11 | criteria provided, multiple submitters, no conflicts | not provided |
![]() ![]() |
Detail |
![]() |
2016-05-31 | no assertion criteria provided | Papillary renal cell carcinoma, sporadic |
![]() |
Detail |
![]() |
2020-05-05 | no assertion criteria provided | Squamous cell lung carcinoma |
![]() |
Detail |
![]() |
2016-05-13 | no assertion criteria provided | carcinoma |
![]() |
Detail |
![]() |
2015-07-14 | no assertion criteria provided | Urinary bladder carcinoma |
![]() |
Detail |
![]() |
2016-05-31 | no assertion criteria provided |
![]() |
Detail | |
![]() |
2016-05-31 | no assertion criteria provided | Squamous cell carcinoma of the head and neck |
![]() |
Detail |
![]() |
2018-10-31 | criteria provided, single submitter | Malignant tumor of testis,Thanatophoric dysplasia type 1,hypochondroplasia,Levy-Hollister syndrome,epidermal nevus,Crouzon syndrome-acanthosis nigricans syndrome,camptodactyly-tall stature-scoliosis-hearing loss syndrome,Malignant tumor of urinary bladder,Thanatophoric dysplasia, type 2,Severe achondroplasia-developmental delay-acanthosis nigricans syndrome,Carcinoma of colon,achondroplasia,cervical cancer,Muenke Syndrome |
![]() |
Detail |
![]() |
2018-10-31 | criteria provided, single submitter | Malignant tumor of testis,Thanatophoric dysplasia type 1,hypochondroplasia,Levy-Hollister syndrome,epidermal nevus,Crouzon syndrome-acanthosis nigricans syndrome,camptodactyly-tall stature-scoliosis-hearing loss syndrome,Malignant tumor of urinary bladder,Thanatophoric dysplasia, type 2,Severe achondroplasia-developmental delay-acanthosis nigricans syndrome,Carcinoma of colon,achondroplasia,cervical cancer,Muenke Syndrome |
![]() |
Detail |
![]() |
2018-10-31 | criteria provided, single submitter | Malignant tumor of testis,Thanatophoric dysplasia type 1,hypochondroplasia,Levy-Hollister syndrome,epidermal nevus,Crouzon syndrome-acanthosis nigricans syndrome,camptodactyly-tall stature-scoliosis-hearing loss syndrome,Malignant tumor of urinary bladder,Thanatophoric dysplasia, type 2,Severe achondroplasia-developmental delay-acanthosis nigricans syndrome,Carcinoma of colon,achondroplasia,cervical cancer,Muenke Syndrome |
![]() |
Detail |
![]() |
2018-10-31 | criteria provided, single submitter | Malignant tumor of testis,Thanatophoric dysplasia type 1,hypochondroplasia,Levy-Hollister syndrome,epidermal nevus,Crouzon syndrome-acanthosis nigricans syndrome,camptodactyly-tall stature-scoliosis-hearing loss syndrome,Malignant tumor of urinary bladder,Thanatophoric dysplasia, type 2,Severe achondroplasia-developmental delay-acanthosis nigricans syndrome,Carcinoma of colon,achondroplasia,cervical cancer,Muenke Syndrome |
![]() |
Detail |
![]() |
2018-10-31 | criteria provided, single submitter | Malignant tumor of testis,Thanatophoric dysplasia type 1,hypochondroplasia,Levy-Hollister syndrome,epidermal nevus,Crouzon syndrome-acanthosis nigricans syndrome,camptodactyly-tall stature-scoliosis-hearing loss syndrome,Malignant tumor of urinary bladder,Thanatophoric dysplasia, type 2,Severe achondroplasia-developmental delay-acanthosis nigricans syndrome,Carcinoma of colon,achondroplasia,cervical cancer,Muenke Syndrome |
![]() |
Detail |
![]() |
2018-10-31 | criteria provided, single submitter | Malignant tumor of testis,Thanatophoric dysplasia type 1,hypochondroplasia,Levy-Hollister syndrome,epidermal nevus,Crouzon syndrome-acanthosis nigricans syndrome,camptodactyly-tall stature-scoliosis-hearing loss syndrome,Malignant tumor of urinary bladder,Thanatophoric dysplasia, type 2,Severe achondroplasia-developmental delay-acanthosis nigricans syndrome,Carcinoma of colon,achondroplasia,cervical cancer,Muenke Syndrome |
![]() |
Detail |
![]() |
2018-10-31 | criteria provided, single submitter | Malignant tumor of testis,Thanatophoric dysplasia type 1,hypochondroplasia,Levy-Hollister syndrome,epidermal nevus,Crouzon syndrome-acanthosis nigricans syndrome,camptodactyly-tall stature-scoliosis-hearing loss syndrome,Malignant tumor of urinary bladder,Thanatophoric dysplasia, type 2,Severe achondroplasia-developmental delay-acanthosis nigricans syndrome,Carcinoma of colon,achondroplasia,cervical cancer,Muenke Syndrome |
![]() |
Detail |
![]() |
2018-10-31 | criteria provided, single submitter | Malignant tumor of testis,Thanatophoric dysplasia type 1,hypochondroplasia,Levy-Hollister syndrome,epidermal nevus,Crouzon syndrome-acanthosis nigricans syndrome,camptodactyly-tall stature-scoliosis-hearing loss syndrome,Malignant tumor of urinary bladder,Thanatophoric dysplasia, type 2,Severe achondroplasia-developmental delay-acanthosis nigricans syndrome,Carcinoma of colon,achondroplasia,cervical cancer,Muenke Syndrome |
![]() |
Detail |
![]() |
2018-10-31 | criteria provided, single submitter | Malignant tumor of testis,Thanatophoric dysplasia type 1,hypochondroplasia,Levy-Hollister syndrome,epidermal nevus,Crouzon syndrome-acanthosis nigricans syndrome,camptodactyly-tall stature-scoliosis-hearing loss syndrome,Malignant tumor of urinary bladder,Thanatophoric dysplasia, type 2,Severe achondroplasia-developmental delay-acanthosis nigricans syndrome,Carcinoma of colon,achondroplasia,cervical cancer,Muenke Syndrome |
![]() |
Detail |
![]() |
2018-10-31 | criteria provided, single submitter | Malignant tumor of testis,Thanatophoric dysplasia type 1,hypochondroplasia,Levy-Hollister syndrome,epidermal nevus,Crouzon syndrome-acanthosis nigricans syndrome,camptodactyly-tall stature-scoliosis-hearing loss syndrome,Malignant tumor of urinary bladder,Thanatophoric dysplasia, type 2,Severe achondroplasia-developmental delay-acanthosis nigricans syndrome,Carcinoma of colon,achondroplasia,cervical cancer,Muenke Syndrome |
![]() |
Detail |
![]() |
2018-10-31 | criteria provided, single submitter | Malignant tumor of testis,Thanatophoric dysplasia type 1,hypochondroplasia,Levy-Hollister syndrome,epidermal nevus,Crouzon syndrome-acanthosis nigricans syndrome,camptodactyly-tall stature-scoliosis-hearing loss syndrome,Malignant tumor of urinary bladder,Thanatophoric dysplasia, type 2,Severe achondroplasia-developmental delay-acanthosis nigricans syndrome,Carcinoma of colon,achondroplasia,cervical cancer,Muenke Syndrome |
![]() |
Detail |
![]() |
2018-10-31 | criteria provided, single submitter | Malignant tumor of testis,Thanatophoric dysplasia type 1,hypochondroplasia,Levy-Hollister syndrome,epidermal nevus,Crouzon syndrome-acanthosis nigricans syndrome,camptodactyly-tall stature-scoliosis-hearing loss syndrome,Malignant tumor of urinary bladder,Thanatophoric dysplasia, type 2,Severe achondroplasia-developmental delay-acanthosis nigricans syndrome,Carcinoma of colon,achondroplasia,cervical cancer,Muenke Syndrome |
![]() |
Detail |
![]() |
2018-10-31 | criteria provided, single submitter | Malignant tumor of testis,Thanatophoric dysplasia type 1,hypochondroplasia,Levy-Hollister syndrome,epidermal nevus,Crouzon syndrome-acanthosis nigricans syndrome,camptodactyly-tall stature-scoliosis-hearing loss syndrome,Malignant tumor of urinary bladder,Thanatophoric dysplasia, type 2,Severe achondroplasia-developmental delay-acanthosis nigricans syndrome,Carcinoma of colon,achondroplasia,cervical cancer,Muenke Syndrome |
![]() |
Detail |
![]() |
2018-10-31 | criteria provided, single submitter | Malignant tumor of testis,Thanatophoric dysplasia type 1,hypochondroplasia,Levy-Hollister syndrome,epidermal nevus,Crouzon syndrome-acanthosis nigricans syndrome,camptodactyly-tall stature-scoliosis-hearing loss syndrome,Malignant tumor of urinary bladder,Thanatophoric dysplasia, type 2,Severe achondroplasia-developmental delay-acanthosis nigricans syndrome,Carcinoma of colon,achondroplasia,cervical cancer,Muenke Syndrome |
![]() |
Detail |
![]() |
2022-06-06 | criteria provided, single submitter | Connective tissue disorder |
![]() |
Detail |
![]() |
2021-11-29 | no assertion criteria provided |
![]() |
Detail | |
![]() |
2024-03-26 | criteria provided, single submitter | achondroplasia |
![]() |
Detail |
![]() |
2022-11-28 | criteria provided, single submitter | FGFR3-related disorder |
![]() |
Detail |
CIViC
Disease | Drug | EL | ET | ED | CS | VO | TR | Pubmed | Links |
---|---|---|---|---|---|---|---|---|---|
transitional cell carcinoma | Pazopanib | C |
![]() |
![]() |
Sensitivity/Response | Somatic | 2 | 25766722 | Detail |
DisGeNET
Score | Disease name | Description | Source | Pubmed | Links |
---|---|---|---|---|---|
0.457 | THANATOPHORIC DYSPLASIA, TYPE I (disorder) | NA | CLINVAR | Detail | |
0.275 | Malignant neoplasm of urinary bladder | Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372... | BeFree | 21264819 | Detail |
0.150 | thanatophoric dysplasia | When the results of the FGFR3 thanatophoric dysplasia mutations located in exon ... | BeFree | 21264819 | Detail |
0.019 | Carcinoma of bladder | Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372... | BeFree | 21264819 | Detail |
0.457 | THANATOPHORIC DYSPLASIA, TYPE I (disorder) | When the results of the FGFR3 thanatophoric dysplasia mutations located in exon ... | BeFree | 21264819 | Detail |
0.255 | seborrheic keratosis | NA | CLINVAR | Detail | |
0.019 | Carcinoma of bladder | Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic targ... | BeFree | 17384684 | Detail |
<0.001 | Carcinoma of urinary bladder, superficial | These results indicate that targeted inhibition of S249C FGFR3 may represent a u... | BeFree | 17384684 | Detail |
0.275 | Malignant neoplasm of urinary bladder | Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic targ... | BeFree | 17384684 | Detail |
0.004 | squamous cell carcinoma | Fibroblast growth factor receptor 3 S249C mutation in virus associated squamous ... | BeFree | 11605053 | Detail |
0.242 | cervix carcinoma | NA | CLINVAR | Detail | |
0.275 | Malignant neoplasm of urinary bladder | NA | CLINVAR | Detail |
Annotation
Annotations
Descrption | Source | Links |
---|---|---|
Case report of a 67 year old woman with high-grade papillary urothelial carcinoma. The patient under... | CIViC Evidence | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND Thanatophoric dysplasia type 1 | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND Cervical cancer | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND Malignant tumor of urinary bladder | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND Seborrheic keratosis | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND not provided | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND Papillary renal cell carcinoma, sporadic | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND Squamous cell lung carcinoma | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND Carcinoma | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND Urinary bladder carcinoma | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND Transitional cell carcinoma of the bladder | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND Squamous cell carcinoma of the head and neck | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND multiple conditions | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND multiple conditions | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND multiple conditions | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND multiple conditions | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND multiple conditions | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND multiple conditions | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND multiple conditions | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND multiple conditions | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND multiple conditions | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND multiple conditions | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND multiple conditions | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND multiple conditions | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND multiple conditions | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND multiple conditions | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND Connective tissue disorder | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND See cases | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND Achondroplasia | ClinVar | Detail |
NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) AND FGFR3-related disorder | ClinVar | Detail |
NA | DisGeNET | Detail |
Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutatio... | DisGeNET | Detail |
When the results of the FGFR3 thanatophoric dysplasia mutations located in exon 7, A248C and S249C a... | DisGeNET | Detail |
Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutatio... | DisGeNET | Detail |
When the results of the FGFR3 thanatophoric dysplasia mutations located in exon 7, A248C and S249C a... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer... | DisGeNET | Detail |
These results indicate that targeted inhibition of S249C FGFR3 may represent a useful therapeutic ap... | DisGeNET | Detail |
Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer... | DisGeNET | Detail |
Fibroblast growth factor receptor 3 S249C mutation in virus associated squamous cell carcinomas. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Overlapped Transcript Coordinates
Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
---|
Overlapped Transcript
Gene | Transcript ID | Chromosome | Start | Stop | Links |
---|
- Gene
- -
- dbSNP
- rs121913483 dbSNP
- Genome
- hg38
- Position
- chr4:1,801,841-1,801,841
- Variant Type
- snv
- Reference Allele
- C
- Alternative Allele
- G
- East Asian Chromosome Counts (ExAC)
- 7854
- East Asian Allele Counts (ExAC)
- 0
- East Asian Heterozygous Counts (ExAC)
- 0
- East Asian Homozygous Counts (ExAC)
- 0
- East Asian Allele Frequency (ExAC)
- 0.0
- Chromosome Counts in All Race (ExAC)
- 103586
- Allele Counts in All Race (ExAC)
- 1
- Heterozygous Counts in All Race (ExAC)
- 1
- Homozygous Counts in All Race (ExAC)
- 0
- Allele Frequency in All Race (ExAC)
- 9.653814221999111E-6
- Variant (CIViC) (CIViC Variant)
- S249C
- Transcript 1 (CIViC Variant)
- ENST00000340107.4
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/628
Genome browser